Published on in Vol 8, No 8 (2019): August

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/14636, first published .
Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial

Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial

Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial

Kazuhiro Yamamoto 1, PhD;  Takeshi Ioroi 1, PhD;  Kenichi Harada 2, MD, PhD;  Satoshi Nishiyama 3, MD, PhD;  Chikako Nishigori 3, MD, PhD;  Ikuko Yano 1, PhD

1 Department of Pharmacy, Kobe University Hospital , Kobe , JP

2 Department of Urology, Graduate School of Medicine, Kobe University, Kobe , JP

3 Division of Dermatology, Department of Internal Related, Graduate School of Medicine, Kobe University, Kobe , JP

Corresponding Author: